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Novel Technology Enables Diagnostic Ultrasound
Machine to Treat Hepatocellular Carcinoma in Mice
Ryan Morrison, Mrigendra B. Karmacharya, Chandra M. Sehgal
Department of Radiology, Perelman School of Medicine
Abstract
An off-the-shelf diagnostic transducer (ULTRASONIX C5-2) was modified
with custom-built circuitry to enable the transducer to produce therapeutic
ultrasound in order to ablate hepatocellular carcinomas grown in
immunodeficient athymic nude mice (25-35 g; Charles River Laboratories,
Wilmington, MA, USA). The therapeutic antivascular ultrasound (AVUS)
produced by the off-the-shelf abdominal transducer was unfocused,
continuous 2.8MHz ultrasound targeting contrast-enhancing perflutren lipid
microbubbles within tumor vasculature. Previous research with a dedicated
physiotherapy ultrasound machine (D150 Plus, Dynatronics Corp., Salt Lake
City, UT, USA) targeting similar hepatocellular carcinomas showed disrupted
tumor neovasculature and irreparable dilation of tumor capillaries with
subsequent intercellular edema and hemorrhage.1-3 In this study, the
echointensity, peak enhancement (PE), perfusion index (PI), and area under
curve (AUC) were measured using non-linear contrast B-mode images
acquired before and after the sham or AVUS treatment. These
measurements all showed the AVUS produced by the diagnostic transducer
markedly decreased tumor blood flow (P < 0.001). In addition, tumor
temperature measurement in the live mice showed that AVUS treatment
markedly increased tumor temperature with a thermal dose (CEM43)
delivered by ultrasound treatment of 124.02 min versus sham of 0 min.
Finally, histochemical staining of the tumor samples taken after AVUS
treatment revealed several hemorrhagic pools in tumors while the shamtreated tumors lack such hemorrhagic pools. This study demonstrates
diagnostic transducers can be enabled to produce AVUS with the ability to
target mural hepatocellular carcinomas.

these mechanical and thermal effects. This study shows that a traditional
diagnostic transducer can be modified to produce these same effects
(Figure 1 and 3) in one machine. This could have large clinical implications
as an inexpensive upgrade to existing diagnostic transducers that unlocks a
new therapeutic modality. In addition, having an all-in-one ultrasound
probe allows for precise targeting of tumor tissue with real-time imaging
feedback during the delivery of the cancer ablating therapy.

Methodology

Figure 4. Echointensity
and peak enhancement
(PE) Pre-Rx and Post-Rx
in sham versus AVUS
shows large decrease in
AVUS in all of the
above measurements
(P < 0.001).

HCC tumors were grown in (n = 5) adult male immunodeficient athymic
nude mice (25-35 g; Charles River Laboratories, Wilmington, MA, USA). The
animal studies were approved by the Institutional Animal Care and Use
Committee (IACUC # 804998). Briefly, mouse hepatoma cells Hepa1-6 (ATCC
CRL-1830; American Type Culture Collection, Manassas, VA, USA) were
injected subcutaneously in the right flank of the mice and grown until they
were 10 mm in diameter. Prior to AVUS treatment, contrast enhanced Bmode images of each tumor were acquired (13–24 MHz; Vevo 2100 system Fujifilm VisualSonics, Toronto, ON, Canada) following the intravenous tailvein injection of 10 μL of the contrast-enhancing microbubbles. For the
AVUS treatment, 50 μL of contrast-enhancing perflutren lipid microbubbles
(Definity, Lantheus Medical Imaging, North Billerica, MA, USA) were injected
and AVUS was cycled for 5 minutes on and 5 minutes off for a total of 30
minutes. After AVUS treatment, contrast enhanced B-mode images of each
tumor were acquired again.

Ultrasonix RP
System

Arbitrary
Waveform
Generator
Figure 1. Left: The custom AVUS therapeutic system is turned off while UltrasonixRP is
scanning in normal diagnostic B-mode. The AVUS system is only enabled when the
operator has the transducer in desired position on the tumor. Right: A close-up image
showing how the custom circuitry sits between the UltrasonixRP system and the
transducer.

AVUS decreased tumor blood flow
Non-linear contrast (NLC) images acquired before (Pre-Rx) and following
(Post-Rx) the sham or AVUS treatment demonstrated that the flow of the
ultrasound-enhancing contrast agents was markedly decreased in the AVUStreated groups. A qualitative examination of the NLC images revealed that, as
opposed to the sham-treated groups where pre- and post-treatment groups
have comparable NLC signals, the AVUS-treated groups have much reduced
NLC signals post-treatment (Figure 2).
Quantitatively, the time-intensity curves, that represent the echointensity of
the NLC images over time, revealed a marked increase in echointensity values
of tumors after the injection of ultrasound-enhancing contrast agent before
AVUS treatment. Notably, there is a significant decrease in the time-intensity
curves after AVUS treatment (Figure 4-5). The time-intensity curves before and
after sham-treatment remain did not change. Additionally, PE, PI, and AUC –
expressed in arbitrary units (a.u.) – measured before (Pre-Rx) vs. after (Post-Rx)
AVUS treatment showed that there is a substantial decrease in these
parameters after AVUS treatment; PE: 23.8 (±1.5) vs. 1.8 (±0.4); PI: 24.3 (±1.1) vs.
1.11 (±0.1); and AUC: 2414.1 (±57.1) vs. 181.3 (±33.6). The difference in PE, PI,
and AUC values between Pre-Rx vs. Post-Rx groups in the AVUS-treated tumors
was statistically significant (P < 0.001). For the sham-treated controls, these
parameters were comparable between Pre-Rx vs. Post-Rx; PE: 23.8 (±3.8) vs.
23.4 (±2.8); PI: 23.8 (±1.5) vs. 24.8 (±2.2); and AUC: 2339.2 (±350.3) vs. 2260.1
(±310.8).

Figure 6. Sham (blue) showed no temperature increase measured inside the
mural HCC while AVUS (orange) showed significant temperature increase

AVUS increased tumor temperature
Tumor temperature measurement in live mice showed that AVUS
treatment markedly increased tumor temperature (Figure 6). The 0 min in
the x-axis represents the onset of the treatment. Thermal dose (CEM43)
delivered by ultrasound treatment was found to be 124.02 min.
AVUS increased tumor hemorrhage
Histochemical staining of the tumor samples taken after AVUS treatment
revealed several hemorrhagic pools in tumors (Figure 7). The sham-treated
tumors lack such hemorrhagic pools.

Figure 2. Left: Non-linear contrast B-mode images acquired before (Pre-Rx) and after (Post-Rx) the sham treatment
showing no reduction in tumor echogenicity. Right: Non-linear contrast B-mode images acquired before (Pre-Rx) and after
(Post-Rx) the AVUS treatment showing dramatic reduction in tumor echogenicity.

Introduction
Hepatocellular carcinoma is the most common primary liver malignancy and
is often treated with resection, systemic chemotherapy, and liver
transplantation if the malignancy is caught early.4 Many advanced tumors,
however, require nonsurgical management with targeted local treatment
methods such as transarterial embolization, thermal ablation, and
4
radioembolization. Antivascular ultrasound therapy defined as low-intensity
ultrasound in combination with microbubble-containing contrast agent
injected into tumor vasculature could become a localized, minimallyinvasive, non-surgical, and inexpensive alternative to treating HCC as well as
4
other cancers. Antivascular ultrasound has been shown to be a potent
tumor disrupting agent as opposed to sonication alone through mechanical
1
and thermal destruction of capillaries in order to deprive tumors of nutriets.
Traditionally, ultrasound machines are separated into diagnostic machines
or specialized ultrasound machines that can deliver enough power to induce

Results
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Figure 3. A block diagram of the AVUS system (Red), UltrasonixRP, and transducer. The
therapeutic system’s custom circuitry printed circuit board sits between the UltrasonixRP to
either allow for normal diagnostic operation of the UltrasonixRP system or inject AVUS
created by the arbitrary waveform generator, RF power amplifier, and impedance
transformer.

Figure 7. Left: Histopathology of mural HCC showing no hemorrhage. Right:
Histopathology of mural HCC showing hemorrhage.

Conclusion
In this preclinical study, five mice with HCC were treated with AVUS from a
diagnostic transducer. The dramatic reduction in tumor vasculature indicates
this treatment is a potential viable alternative to several other HCC
treatments. This study was a necessary step so that AVUS can eventually be
translated into the clinical setting, which could provide a cost-effective
upgrade to older ultrasound equipment that would enable a wide range of
therapeutic applications.
Figure 5. Perfusion
index (PI), and area
under curve (AUC),
Pre-Rx and Post-Rx in
sham versus AVUS
shows large decrease
in AVUS in all of the
above measurements
(P < 0.001).
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